Dr. Reddy’s Laboratories secured European Commission approval for AVT03, a biosimilar to Prolia and Xgeva, for osteoporosis and bone complications. This significant milestone, following a positive CHMP recommendation, allows marketing across EU member states and EEA countries. Dr. Reddy’s, in partnership with Alvotech, will commercialize the drug under brands Acyvbra and Xbonzy.
Dr. Reddy’s Laboratories shares jump over 1% as European Commission approves biosimilar AVT03
📅 Published: November 25, 2025 |
📂 Category: Uncategorized